Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.66 USD | +3.74% | +19.57% | -24.83% |
May. 13 | JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating | MT |
May. 10 | Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.83% | 742M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- PRME Stock
- News Prime Medicine, Inc.
- Chardan Initiates Prime Medicine With Buy Rating, Price Target is $17